{
    "title": "New MS drug lifts Roche as biosimilars bite in Europe",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4995772/Roche-Q3-sales-beat-forecasts-Ocrevus-shines.html",
    "date": "2017-10-19",
    "keywords": [
        "percent",
        "cancer",
        "roche",
        "europe",
        "analyst",
        "quarter",
        "rituxan",
        "herceptin",
        "tecentriq",
        "lung",
        "study",
        "miller",
        "revenue",
        "medicine",
        "year",
        "avastin",
        "vision",
        "bladder",
        "sclerosis",
        "drug",
        "ocrevus",
        "blow",
        "company",
        "group",
        "estimate",
        "poll",
        "average",
        "seller",
        "novartis",
        "celltrion",
        "competition",
        "unit",
        "dan",
        "oday",
        "thursday",
        "effect",
        "world",
        "gmt",
        "august",
        "stock",
        "health",
        "care",
        "rise",
        "looming",
        "threat",
        "view",
        "example",
        "impact",
        "nawrath",
        "market",
        "weight",
        "rating",
        "half",
        "business",
        "july",
        "september",
        "thomson",
        "tim",
        "anderson",
        "digit",
        "rate",
        "exchange",
        "executive",
        "severin",
        "schwan",
        "share",
        "line",
        "immunotherapy",
        "period",
        "combination",
        "decline",
        "treatment",
        "chemotherapy",
        "end",
        "impower",
        "decisive",
        "growth",
        "bulic",
        "baader",
        "helvea",
        "reporting",
        "john",
        "michael",
        "david"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}